SCHEMBL12809359

SCHEMBL12809359

CCOC(=O)[C@H]1CC[C@@H](Oc2ccc(NC(=O)c3nnc(Nc4cc(F)c(F)cc4F)o3)c([N+](=O)[O-])c2)CC1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 12/20 0.67
SOAT1 P35610 11/20 0.67
MAPT P10636 4/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 1/20 0.44
MAPK1 P28482 1/20 0.44
TP53 P04637 1/20 0.41
NPC1 O15118 4/20 0.40
RAB9A P51151 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
GAA P10253 1/20 0.40
DGAT2 Q96PD7 1/20 0.39
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12809187 1.00 DGAT1 (0.67) DGAT1SOAT1MAPTALDH1A1HPGD
SCHEMBL14336237 1.00 DGAT1 (0.67) DGAT1SOAT1MAPTALDH1A1HPGD
SCHEMBL1399582 0.91 DGAT1 (0.81) DGAT1SOAT1MAPTALDH1A1HPGD
SCHEMBL1399583 0.91 DGAT1 (0.81) DGAT1SOAT1MAPTALDH1A1HPGD
SCHEMBL2242437 0.91 DGAT1 (0.81) DGAT1SOAT1DGAT2
SCHEMBL2242430 0.91 DGAT1 (0.81) DGAT1SOAT1DGAT2
SCHEMBL2244888 0.91 DGAT1 (0.81) DGAT1SOAT1DGAT2
SCHEMBL14336182 0.90 DGAT1 (0.59) DGAT1SOAT1MAPTALDH1A1HPGD
SCHEMBL13747427 0.90 DGAT1 (0.59) DGAT1SOAT1MAPTALDH1A1HPGD
SCHEMBL12809140 0.88 DGAT1 (0.72) DGAT1SOAT1DGAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2035417-B1 BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES ASTRAZENECA AB (SE) 2011-03-02 EP disclosed
US-20090197926-A1 BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES ASTRAZENECA AB (SE) 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197926-A1 BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES DGAT1, ACAT1, DGAT2 DGAT1 1/4885SOAT1 5/4885MAPT 2285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.